Beam Therapeutics Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +158.0%
EBITDA: +92.0%
EBIT: +13.7%
EPS: +86.1%
Free cash flow: -6.3%
Operating cash flow: -5.2%

Forward estimates

Revenue: -73.2%
EBITDA: +1.2%
EPS: —

Three-year CAGR

Revenue: +31.9%
EBITDA: +91.6%
EBIT: +7.7%
Net income: +78.8%
EPS: +82.3%
Free cash flow: -1.1%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.